EuroBiotech—More Articles of Note


> Oncopeptides presented interim data phase 2 on melflufen in late-stage relapsed-refractory multiple myeloma patients. One-third of patients had responded to the drug as of the cutoff. Release 

> Nordic Nanovector shared updated phase 2 data in relapsed indolent non-Hodgkin's lymphoma. The updated data featured two more complete responses in patients taking Betalutin. Statement

> Autolus Therapeutics posted data on its next-generation CAR-T candidate AUTO3. The one-month manufacturing time and high rate of relapse cast a shadow over the overall response data. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Freeline Therapeutics released early data on its pitch for the hemophilia B gene therapy market. The two patients who received a single infusion of the lowest dose achieved mean factor IX activity levels of 45%. Statement

> MaaT Pharma published results from a phase 1b/2a trial of its microbiome drug in patients with acute myeloid leukemia. The trial found the drug restored 90% of microbial species diversity within 40 days. Release 

> Mereo Biopharma struck a deal to merge with OncoMed Pharmaceuticals. The merger will give Mereo a Nasdaq listing and an expanded pipeline. Statement 

Suggested Articles

Nektar Therapeutics created Inheris Biopharma, a new subsidiary that will take over the launch of Nektar’s pain drug, NKTR-181.

In this week's EuroBiotech Report, Novartis bests GSK in asthma trial, Affimed scraps T-cell engager program and Amgen inks Nuevolution buyout.

Using liver “organoids,” a Dutch team has gained insight into how the mutated BAP1 gene contributes to liver cancer.